Skip to main content
SpringerLink
Log in
Book cover

Antibiotic Pharmacodynamics pp 317–343Cite as

Pharmacodynamics of Daptomycin

  • Protocol
  • First Online:

Part of the book series: Methods in Pharmacology and Toxicology ((MIPT))

Abstract

The pharmacokinetics and pharmacodynamics of daptomycin have been extensively explored in a host of in vitro models, multiple different patient populations, and clinical studies. Daptomycin exhibits concentration-dependent bactericidal activity with the ratio of unbound area-under-the-curve to minimum inhibitory concentration (fAUC/MIC) best predicting antibacterial efficacy in vitro. The large body of evidence suggests that higher doses (e.g., 8–10 mg/kg) of daptomycin are more effective and equally safe and should be used for specific pathogens (i.e., methicillin-resistant Staphylococcus aureus, Enterococcus) and in certain patient scenarios (i.e., critically ill, bacteremia, endocarditis). The emergence of resistance to daptomycin during therapy and clinical failure in serious infections brings its efficacy as monotherapy into question while the ease of administration, dosing schedule, and lack of nephrotoxicity continues to drive its use until more reliable therapeutic alternatives for gram-positive infections are established.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Allen NE, Alborn WE Jr, Hobbs JN Jr (1991) Inhibition of membrane potential-dependent amino acid transport by daptomycin. Antimicrob Agents Chemother 35(12):2639–2642

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Straus SK, Hancock RE (2006) Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim Biophys Acta 1758(9):1215–1223

    Article  CAS  PubMed  Google Scholar 

  3. Fuchs PC, Barry AL, Brown SD (2002) In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother 49(3):467–470

    Article  CAS  PubMed  Google Scholar 

  4. Dvorchik B, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H (2004) Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother 48(8):2799–2807

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Tally FP, DeBruin MF (2000) Development of daptomycin for gram-positive infections. J Antimicrob Chemother 46(4):523–526

    Article  CAS  PubMed  Google Scholar 

  6. Garrison MW, Rotschafer JC, Crossley KB (1989) Suboptimal effect of daptomycin in the treatment of bacteremias. South Med J 82(11):1414–1415

    Article  CAS  PubMed  Google Scholar 

  7. Garrison MW, Vance-Bryan K, Larson TA, Toscano JP, Rotschafer JC (1990) Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model. Antimicrob Agents Chemother 34(10):1925–1931

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Rybak MJ, Bailey EM, Lamp KC, Kaatz GW (1992) Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia. Antimicrob Agents Chemother 36(5):1109–1114

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Woodworth JR, Nyhart EH Jr, Brier GL, Wolny JD, Black HR (1992) Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 36(2):318–325

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD (2003) Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 47(4):1318–1323

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Benvenuto M, Benziger DP, Yankelev S, Vigliani G (2006) Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 50(10):3245–3249

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Chakraborty A, Roy S, Loeffler J, Chaves RL (2009) Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. J Antimicrob Chemother 64(1):151–158

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Chaves RL, Chakraborty A, Benziger D, Tannenbaum S (2014) Clinical and pharmacokinetic considerations for the use of daptomycin in patients with Staphylococcus aureus bacteremia and severe renal impairment. J Antimicrob Chemother 69:200–210

    Article  CAS  PubMed  Google Scholar 

  14. Di Paolo A, Tascini C, Polillo M, Gemignani G, Nielsen EI, Bocci G, Karlsson MO, Menichetti F, Danesi R (2013) Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections. Int J Antimicrob Agents 42(3):250–255

    Article  PubMed  CAS  Google Scholar 

  15. Falcone M, Russo A, Venditti M, Novelli A, Pai MP (2013) Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 57(11):1568–1576

    Article  CAS  PubMed  Google Scholar 

  16. Soon RL, Turner SJ, Forrest A, Tsuji BT, Brown J (2013) Pharmacokinetic/pharmacodynamic evluation of the efficacy and safety of daptomycin against Staphylococcus aureus. Int J Antimicrob Agnets 42:53–58

    Article  CAS  Google Scholar 

  17. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL (2010) Daptomycin exposure and the probability of elevations in the creatinine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 50:1568–1574

    Article  CAS  PubMed  Google Scholar 

  18. Cohen-Wolkowiez M, Watt KM, Hornik CP, Benjamin DK Jr, Smith PB (2012) Pharmacokinetics and tolerability of single-dose daptomycin in young infants. Pediatr Infect Dis J 31(9):935–937

    Article  PubMed  PubMed Central  Google Scholar 

  19. Cohen-Wolkowiez M, Smith PB, Benjamin DK Jr, Fowler VG Jr, Wade KC (2008) Daptomycin use in infants: report of two cases with peak and trough drug concentrations. J Perinatol 28(3):233–234

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Antachopoulos C, Iosifidis E, Sarafidis K, Bazoti F, Gikas E, Katragkou A, Drossou-Agakidou V, Roilides E (2012) Serum levels of daptomycin in pediatric patients. Infection 40(4):367–371

    Article  CAS  PubMed  Google Scholar 

  21. Bradley JS, Benziger D, Bokesch P, Jacobs R (2014) Single-dose pharmacokinetics of daptomycin in pediatric patients 3-24 months of age. Pediatri Infect Dis J 33(9):936–939

    Article  Google Scholar 

  22. Abdel-Rahman SM, Benziger DP, Jacobs RF, Jafri HS, Hong EF, Kearns GL (2008) Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Pediatr Infect Dis J 27(4):330–334

    Article  PubMed  Google Scholar 

  23. Abdel-Rahman SM, Chandorkar G, Akins RL, Bradley JS, Jacobs RF, Donovan J, Benziger DP (2011) Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10 mg/kg in children aged 2 to 6 years with suspected or proved Gram-positive infections. Pediatr Infect Dis J 30(8):712–714

    Article  PubMed  Google Scholar 

  24. Dvorchik B, Damphousse D (2004) Single-dose pharmacokinetics of daptomycin in young and geriatric volunteers. J Clin Pharmacol 44(6):612–620

    Article  CAS  PubMed  Google Scholar 

  25. Pai MP, Norenberg JP, Anderson T, Goade DW, Rodvold KA, Telepak RA, Merceier R-C (2007) Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother 51(8):2741–2747

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Dvorchik BH, Damphousse D (2005) The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol 45(1):48–56

    Article  CAS  PubMed  Google Scholar 

  27. Pai MP (2012) Drug dosing based on weight and body surface area: mathematical assumptions and limitations of obese adults. Pharmacotherapy 32:856–868

    Article  PubMed  Google Scholar 

  28. Di Paolo A, Polillo M, Tascini C, Lewis R, Menichetti F, Danesi R (2014) Different recommendations for daptomycin dosing over time in patients with severe infections. Clin Infect Dis 58(12):1788–1789

    Article  PubMed  Google Scholar 

  29. Falcone M, Russo A, Venditti M, Novelli A, Pai MP. Reply to Di Paolo et al (2014) Clin Infect Dis 58(12):1789–1790

    Google Scholar 

  30. Ng JK, Schulz LT, Rose WE, Fox BC, Andes DR, Buhr KA, Fish JT (2014) Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes. Antimicrob Agents Chemother 58:88–93

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Pai MP, Russo A, Novelli A, Venditti M, Flacone M (2014) Simplified equations using two concentrations to calculate area under the curve for antimicrobials with concentration-dependent pharmacodynamics: daptomycin as a motivating example. Antimicrob Agents Chemother 58(6):3162–3167

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Bubalo JS, Munar MY, Cherala G, Hayes-Lattin B, Maziarz R (2009) Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemother 53(2):428–434

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Mohr JF 3rd, Ostrosky-Zeichner L, Wainright DJ, Parks DH, Hollenbeck TC, Ericsson CD (2008) Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury. Antimicrob Agents Chemother 52(5):1891–1893

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Erritouni M, Ktaich N, Rahal JJ et al (2012) Use of daptomycin for the treatment of methicillin-resistant coagulase-negative staphylococcal ventriculitis. Case Rep Med 2012:593578

    PubMed  PubMed Central  Google Scholar 

  35. Wahby KA, Alangaden GJ (2012) Daptomycin failure in a neutropenic leukemia patient with Staphylococcus aureus meningitis. Leuk Lymphoma 53(8):1610–1612

    Article  CAS  PubMed  Google Scholar 

  36. Kelesidis T, Humphries R, Ward K, Lewinski MA, Yang OO (2011) Combination therapy with daptomycin, linezolid, and rifampin as treatment option for MRSA meningitis and bacteremia. Diagn Microbiol Infect Dis 71(3):286–290

    Article  CAS  PubMed  Google Scholar 

  37. Le J, Bookstaver PB, Rudisill CN, Hashem MG, Igbal R, James CL, Sakoulas G (2010) Treatment of meningitis caused by vancomycin-resistant Enterococcus faecium: high-dose and combination daptomycin therapy. Ann Pharmacother 44(12):2001–2006

    Article  PubMed  Google Scholar 

  38. Riser MS, Bland CM, Rudisill CN, Bookstaver PB (2010) Cerebrospinal fluid penetration of high-dose daptomycin in suspected Staphylococcus aureus meningitis. Ann Pharmacother 44(11):1832–1835

    Article  PubMed  Google Scholar 

  39. Jaspan HB, Brothers AW, Campbell AJ, McGuire JK, Browd SR, Manley TJ, Park D, Weissman SJ (2010) Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline. Pediatr Infect Dis J 29(4):379–381

    PubMed  PubMed Central  Google Scholar 

  40. Lee DH, Palermo B, Chowdhury M (2008) Successful treatment of methicillin-resistant Staphylococcus aureus meningitis with daptomycin. Clin Infect Dis 47(4):588–590

    Article  PubMed  Google Scholar 

  41. Taglietti F, Campanile F, Capone A et al (2012) Daptomycin efficacy in the central nervous system of a patient with disseminated methicillin-resistant Staphylococcus aureus infection: a case report. J Med Case Rep 6:264

    Article  PubMed  PubMed Central  Google Scholar 

  42. Kullar R, Chin JN, Edwards DJ, Parker D, Coplin WM, Rybak MJ (2011) Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections. Antimicrob Agents Chemother 55(7):3505–3509

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Vivas M, Force E, Garrigos C et al (2014) Experimental study of the efficacy of daptomycin for the treatment of cephalosporin-resistant pneumococcal meningitis. J Antimicrob Chemother 69(11):3020–3026

    Article  CAS  PubMed  Google Scholar 

  44. Cardone KE, Lodise TP, Patel N, Hoy CD, Meola S, Manley HJ, Drusano GL, Grabe DW (2011) Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis. Clin J Am Soc Nephrol 6(5):1081–1088

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Goedecke VA, Clajus C, Burkhardt O, Martens-Lobenhoffer J, Bode-Boger SM, Kielstein JT, Hiss M (2009) Pharmacokinetics and dialysate levels of daptomycin given intravenously in a peritoneal dialysis patient. Scand J Infect Dis 41(2):155–157

    Article  CAS  PubMed  Google Scholar 

  46. Bahte SK, Bertram A, Burkhardt O, Martens-Lebenhoffer J, Goedecke V, Bode-Boger SM, Hiss M, Kielstein JT (2010) Therapeutic serum concentrations of daptomycin after intraperitoneal administration in a patient with peritoneal dialysis-associated peritonitis. J Antimicro Chemother 65(6):1312–1314

    Article  CAS  Google Scholar 

  47. Huen SC, Hall I, Topal J, Mahnensmith RL, Brewster UC, Abu-Alfa AK (2009) Successful use of intraperitoneal daptomycin in the treatment of vancomycin-resistant Enterococcus peritonitis. Am J Kidney Dis 54(3):538–541

    Article  PubMed  Google Scholar 

  48. Benziger DP, Pertel PE, Donovan J, Yankelev S, Schwab RJ, Swan SK, Cannon C (2011) Pharmacokinetics and safety of multiple doses of daptomycin 6 mg/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Clin Nephrol 75(1):63–69

    CAS  PubMed  Google Scholar 

  49. Salama NN, Segal JH, Churchwell MD, Patel JH, Gao L, Heung M, Mueller BA (2010) Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients. Nephrol Dial Transplant 25(4):1279–1284

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Salama NN, Segal JH, Churchwell MD, Patel JH, Gao L, Heung M, Mueller BA (2009) Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis. Clin J Am Soc Nephrol 4(7):1190–1194

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Patel N, Cardone K, Grabe DW, Meola S, Hoy C, Manely H, Drusano GL, Lodise TP (2011) Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis. Antimicrob Agents Chemother 55(4):1677–1683

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Butterfield JM, Mueller BA, Patel N, Cardone KE, Grabe DW, Salama NN, Lodise TP (2013) Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis. Antimicrob Agents Chemother 57(2):864–872

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Churchwell MD, Pasko DA, Mueller BA (2006) Daptomycin clearance during modelled continuous renal replacement therapy. Blood Purif 24:548–554

    Article  CAS  PubMed  Google Scholar 

  54. Wagner CC, Steiner I, Zeitlinger M (2009) Daptomycin elimination by CVVH in vitro: evaluation of factors influencing sieving and membrane adsorption. Int J Clin Pharmacol Ther 47(3):178–186

    Article  CAS  PubMed  Google Scholar 

  55. Burkhardt O, Joukhadar C, Traunmuller F, Hadem J, Welte T, Kielstein JT (2008) Elimination of daptomycin in a patient with acute renal failure undergoing extended daily dialysis. J Antimicrob Chemother 61:224–225

    Article  CAS  PubMed  Google Scholar 

  56. Kielstein JT, Engbers C, Bode-Boeger SM, Martens-Lobenhoffer J, Haller H, Joukhadar C, Traunmuller F, Kritsch W, Hafer C, Burkhardt O (2010) Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis: a pharmacokinetic study. Nephrol Dial Transplant 25:1537–1541

    Article  CAS  PubMed  Google Scholar 

  57. Khadzhynov D, Slowinski T, Lieker I, Spies C, Puhlmann B, Konig T, Uhrig A, Eggers K, Neumayer H-H, Traunmuller F, Joukhader C, Peters H (2011) Plasma pharmacokinetics of daptomycin in critically ill patients with renal failure and undergoing CVVHD. Int J Clin Pharmacol Ther 49(11):656–665

    Article  CAS  PubMed  Google Scholar 

  58. Vilay AM, Grio M, DePestel DD, Sowinski KM, Gao L, Heung M, Salama NN, Mueller BA (2011) Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Crit Care Med 39(1):19–25

    Article  CAS  PubMed  Google Scholar 

  59. Rudiger A, Rentsch K, Maggiorini M, Corti N (2011) Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis (Letter). Crit Care Med 39(5):1243–1244

    Article  PubMed  Google Scholar 

  60. Vilay AM, DePestel DD, Mueller BA (2011) Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis (Letter). Crit Care Med 39(5):1244–1245

    Article  Google Scholar 

  61. Wenisch JM, Meyer B, Fuhrmann V, Saria K, Zuba C, Dittrich P, Thalhammer F (2012) Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration. J Antimicrob Chemother 67(4):977–983

    Article  CAS  PubMed  Google Scholar 

  62. Preiswerk B, Rudiger A, Fehr J, Corti N (2013) Experience with daptomycin daily dosing in ICU patients undergoing continuous renal replacement therapy. Infection 41:533–537

    Article  CAS  Google Scholar 

  63. Corti N, Rudiger A, Chiesa A, Marti I, Jetter A, Rentsch K, Muller D, Bechir M, Maggiorini M (2013) Pharmacokinetics of daily daptomycin in critically ill patients undergoing continuous renal replacement therapy. Chemotherapy 59(2):143–151

    Article  CAS  PubMed  Google Scholar 

  64. Falcone M, Russo A, Cassetta MI, Lappa A, Tritapepe L, Fallani S, Vullo V, Venditti M, Novelli A (2012) Daptomycin serum levels in critical patients undergoing continuous renal replacement. J Chemother 24:253–256

    Article  CAS  PubMed  Google Scholar 

  65. Wise R, Gee T, Andrews JM, Dvorchik B, Marshall G (2002) Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother 46(1):31–33

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Kim A, Suecof LA, Sutherland CA, Gao L, Kuti JL, Nicolau DP (2008) In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers. Antimicrob Agents Chemother 52(11):3941–3946

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Montange D, Berthier F, Leclerc G, Serre A, Jeunet L, Berard M, Muret P, Vettoretti L, Leroy J, Hoen B, Chirouze C et al (2014) Penetration of daptomycin into bone and synovial fluid in joint replacement. Antimicrob Agents Chemother 58(7):3991–3996

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Ritchie ND, Lovering AM, Seaton RA (2010) Daptomycin in synovial fluid during treatment of methicillin-resistant Staphylococcus aureus septic arthritis. J Antimicrob Chemother 65(6):1314–1315

    Article  CAS  PubMed  Google Scholar 

  69. Traunmuller F, Schintler MV, Metzler J, Spendel S, Mauric O, Popovic M, Konz KH, Scharnagi E, Joukhader C (2010) Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother 65(6):1252–1257

    Article  PubMed  CAS  Google Scholar 

  70. Tascini C, Di Paolo A, Poletti R, Flammini S, Emdin M, Ciullo I, Tagliaferri E, Moter A, Menichetti F (2013) Daptomycin concentrations in valve tissue and vegetation in patients with bacterial endocarditis. Antimicrob Agents Chemother 57(1):601–602

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Nguyen MH, Eells SJ, Tan J, Sheth CT, Omari B, Flores M, Wang J, Miller LG (2011) Prospective, open-label investigations of the pharmacokinetics of daptomycin during cardiopulmonary bypass surgery. Antimicrob Agents Chemother 55(6):2499–2505

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Sheridan KR, Potoski BA, Shields RK, Nau GJ (2010) Presence of adequate intravitreal concentrations of daptomycin after systemic intravenous administration in a patient with endogenous endophthalmitis. Pharmacotherapy 30(12):1247–1251

    Article  PubMed  Google Scholar 

  73. Hanberger H, Nilsson LE, Maller R, Isaksson B (1991) Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob Agents Chemother 35(9):1710–1716

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Cha R, Rybak MJ (2004) Influence of protein binding under controlled conditions on the bactericidal activity of daptomycin in an in vitro pharmacodynamic model. J Antimicrob Chemother 54(1):259–262

    Article  CAS  PubMed  Google Scholar 

  75. Cha R, Grucz RG Jr, Rybak MJ (2003) Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother 47(5):1598–1603

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Asin E, Isla A, Canut A, Rodriguez GA (2012) Comparison of antimicrobial pharmacokinetic/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria. Int J Antimicrob Agents 40(4):313–322

    Article  CAS  PubMed  Google Scholar 

  77. Hall AD, Steed ME, Arias CA, Murray BE, Rybak MJ (2012) Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 56(6):3174–3180

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Luther MK, Arvanitis M, Mylonakis E, LaPlante KL (2014) Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae. Antimicrob Agents Chemother 58(8):4612–4620

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  79. Hall Snyder A, Werth BJ, Barber KE, Sakoulas G, Rybak MJ (2014) Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model. J Antimicrob Chemother 69(8):2148–2154

    Article  CAS  PubMed  Google Scholar 

  80. Werth BJ, Steed ME, Ireland CE et al (2014) Defining daptomycin resistance prevention exposures in vancomycin resistant Enterococcus (VRE) faecium and E. faecalis. Antimicrob Agents Chemother 58(9):5253–5261

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Bhalodi AA, Hagihara M, Nicolau DP, Kuti JL (2014) In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure. Antimicrob Agents Chemother 58(2):672–677

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  82. LaPlante KL, Rybak MJ (2004) Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 48(12):4665–4672

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Rose WE, Leonard SN, Rybak MJ (2008) Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 52(9):3061–3067

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Steed M, Vidaillac C, Rybak MJ (2011) Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 55(7):3522–3526

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Safdar N, Andes D, Craig WA (2004) In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 48(1):63–68

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL (2001) Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 45(3):845–851

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Dandekar PK, Tessier PR, Williams P, Nightingale CH, Nicolau DP (2003) Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J Antimicrob Chemother 52(3):405–411

    Article  CAS  PubMed  Google Scholar 

  88. Dandekar PK, Tessier PR, Williams P, Zhang C, Nightingale CH, Nicolau DP (2004) Determination of the pharmacodynamic profile of daptomycin against Streptococcus pneumoniae isolates with varying susceptibility to penicillin in a murine thigh infection model. Chemotherapy 50(1):11–16

    Article  CAS  PubMed  Google Scholar 

  89. Gerber P, Stucki A, Acosta F, Cottagnoud M, Cottagnoud P (2006) Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis. J Antimicrob Chemother 57(4):720–723

    Article  CAS  PubMed  Google Scholar 

  90. Cottagnoud P, Pfister M, Acosta F et al (2004) Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 48(10):3928–3933

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Ramos MC, Grayson ML, Eliopoulos GM, Bayer AS (1992) Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endocarditis caused by penicillin-resistant enterococci. Antimicrob Agents Chemother 36(9):1864–1869

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Bush LM, Boscia JA, Kaye D (1988) Daptomycin (LY146032) treatment of experimental enterococcal endocarditis. Antimicrob Agents Chemother 32(6):877–881

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Kennedy S, Chambers HF (1989) Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits. Antimicrob Agents Chemother 33(9):1522–1525

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. El Haj C, Murillo O, Ribera A et al (2014) Comparative efficacies of cloxacillin-daptomycin and the standard cloxacillin-rifampin therapies against an experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 58(9):5576–5580

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  95. Garrigos C, Murillo O, Lora-Tamayo J et al (2012) Efficacy of daptomycin-cloxacillin combination in experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 56(7):3806–3811

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Housman ST, Sutherland CA, Nicolau DP (2014) Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals. Int J Antimicrob Agents

    Google Scholar 

  97. Soon RL, Turner SJ, Forrest A, Tsuji BT, Brown J (2013) Pharmacokinetic/pharmacodynamic evaluation of the efficacy and safety of daptomycin against Staphylococcus aureus. Int J Antimicrob Agents 42(1):53–58

    Article  CAS  PubMed  Google Scholar 

  98. Canut A, Isla A, Betriu C, Gascon AR (2012) Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries. Eur J Clin Microbiol Infect Dis 31(9):2227–2235

    Article  CAS  PubMed  Google Scholar 

  99. Salem AH, Zhanel GG, Ibrahim SA, Noreddin AM (2014) Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus. Clin Exp Pharmacol Physiol 41(6):437–443

    Article  CAS  PubMed  Google Scholar 

  100. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI (2004) The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 38(12):1673–1681

    Article  CAS  PubMed  Google Scholar 

  101. Konychev A, Heep M, Moritz RK et al (2013) Safety and efficacy of daptomycin as first-line treatment for complicated skin and soft tissue infections in elderly patients: an open-label, multicentre, randomized phase IIIb trial. Drugs Aging 30(10):829–836

    Article  CAS  PubMed  Google Scholar 

  102. Aikawa N, Kusachi S, Mikamo H et al (2013) Efficacy and safety of intravenous daptomycin in Japanese patients with skin and soft tissue infections. J Infect Chemother 19(3):447–455

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Pertel PE, Eisenstein BI, Link AS et al (2009) The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. Int J Clin Pract 63(3):368–375

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Katz DE, Lindfield KC, Steenbergen JN et al (2008) A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract 62(9):1455–1464

    Article  CAS  PubMed  Google Scholar 

  105. Byren I, Rege S, Campanaro E et al (2012) Randomized controlled trial of the safety and efficacy of daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty. Antimicrob Agents Chemother 56(11):5626–5632

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Fowler VG Jr, Boucher HW, Corey GR et al (2006) Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355(7):653–665

    Article  CAS  PubMed  Google Scholar 

  107. Carugati M, Bayer AS, Miro JM et al (2013) High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis. Antimicrob Agents Chemother 57(12):6213–6222

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Kullar R, Casapao AM, Davis SL et al (2013) A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. J Antimicrob Chemother 68(12):2921–2926

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Sakoulas G, Moise PA, Casapao AM et al (2014) Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther 36(10):1317–1333

    Article  CAS  PubMed  Google Scholar 

  110. Pertel PE, Bernardo P, Fogarty C et al (2008) Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 46:1142–1151

    Article  CAS  PubMed  Google Scholar 

  111. Silverman JA, Mortin LI, Vanpraagh AD et al (2003) Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 47:2538–2544

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA

    Eric Wenzler

  2. Department of Pharmacy, University of Cincinnati Medical Center, Cincinnati, OH, USA

    Siyun Liao

  3. Colleges of Pharmacy and Medicine, University of Illinois at Chicago, Chicago, IL, USA

    Keith A. Rodvold Pharm.D.

Authors
  1. Eric Wenzler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Siyun Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keith A. Rodvold Pharm.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keith A. Rodvold Pharm.D. .

Editor information

Editors and Affiliations

  1. College of Pharmacolgy,Univ of Minnesota, Dept of Experimental and Clinical Pharma, Minneapolis, Minnesota, USA

    John C. Rotschafer

  2. Division of Infectious Diseases, University of Wisconsin, Madison, Wisconsin, USA

    David R. Andes

  3. College of Pharmacy and Medicine, University of Illinois, Chicago, Illinois, USA

    Keith A. Rodvold

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media New York

About this protocol

Cite this protocol

Wenzler, E., Liao, S., Rodvold, K.A. (2016). Pharmacodynamics of Daptomycin. In: Rotschafer, J., Andes, D., Rodvold, K. (eds) Antibiotic Pharmacodynamics. Methods in Pharmacology and Toxicology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3323-5_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-3323-5_13

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-3321-1

  • Online ISBN: 978-1-4939-3323-5

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation